Cyclin Dependent Kinase 2 Research Report: Competitor, Under Development Projects, Mergers and Acquisition, Discontinued Projects and more
Cyclin Dependent Kinase 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Cyclin Dependent Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
(EMAILWIRE.COM, April 03, 2018 ) Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B). The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 1 and 2 respectively.
Report Source: https://www.themarketreports.com/report/cyclin-dependent-kinase-2-p33-protein-kinase-or-cell-division-protein-kinase-2-or-cdk2-or-ec-271122-pipeline-review-h1-2018
Scope
The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
The report reviews Cyclin Dependent Kinase 2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Cyclin Dependent Kinase 2 targeted therapeutics and enlists all their major and minor projects
Purchase this report at: https://www.themarketreports.com/report/buy-now/968362
Reasons To Buy
Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/968362
Report Source: https://www.themarketreports.com/report/cyclin-dependent-kinase-2-p33-protein-kinase-or-cell-division-protein-kinase-2-or-cdk2-or-ec-271122-pipeline-review-h1-2018
Scope
The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
The report reviews Cyclin Dependent Kinase 2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Cyclin Dependent Kinase 2 targeted therapeutics and enlists all their major and minor projects
Purchase this report at: https://www.themarketreports.com/report/buy-now/968362
Reasons To Buy
Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/968362
Contact Information:
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results